×
About 170 results

ALLMedicine™ Mediastinal Lymphoma Center

Research & Reviews  57 results

Recurrent Syncope in a Case with Mediastinal Lymphoma.
https://doi.org/10.1536/ihj.21-768
International Heart Journal; Nagano M, Misumi I et. al.

May 16th, 2022 - An 83-year-old man suddenly lost consciousness, and his blood pressure dropped. Results of blood analysis were within normal range. A chest radiograph showed enlargement of the left mediastinum. Computed tomographic scan of the chest showed a larg...

Positron emission tomography/computed tomography differentiates resectable thymoma from...
https://doi.org/10.1016/j.jtcvs.2022.02.055
The Journal of Thoracic and Cardiovascular Surgery; Byrd CT, Trope WL et. al.

May 15th, 2022 - Discrete anterior mediastinal masses most often represent thymoma or lymphoma. Lymphoma treatment is nonsurgical and requires biopsy. Noninvasive thymoma is ideally resected without biopsy, which may potentiate pleural metastases. This study sough...

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnos...
https://clinicaltrials.gov/ct2/show/NCT01599559

May 9th, 2022 - Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be ...

Mediastinal Lymphoma
https://emedicine.medscape.com/article/203681-print

May 4th, 2022 - Primary mediastinal B-cell lymphoma (PMBCL) is relatively rare B-cell non-Hodgkin lymphoma that comprises 6–12% of all diffuse large B-cell lymphomas (DLBCLs) and 2–4% of all non-Hodgkin lymphomas. PMBCL affects young adults in their third to four...

Mediastinal Lymphoma
http://emedicine.medscape.com/article/203681-overview

May 4th, 2022 - Practice Essentials Primary mediastinal B-cell lymphoma (PMBCL) is relatively rare B-cell non-Hodgkin lymphoma that comprises 6–12% of all diffuse large B-cell lymphomas (DLBCLs) and 2–4% of all non-Hodgkin lymphomas. PMBCL affects young adults in...

see more →

Clinicaltrials.gov  7 results

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnos...
https://clinicaltrials.gov/ct2/show/NCT01599559

May 9th, 2022 - Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be ...

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
https://clinicaltrials.gov/ct2/show/NCT04892433

Mar 31st, 2022 - The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of oncohematological pathologies that have not resp...

Radiotherapy Delivery in Deep Inspiration for Pediatric Patients
https://clinicaltrials.gov/ct2/show/NCT03315546

Oct 9th, 2020 - Background: The majority (approximately 80%) of pediatric patients with cancer become long-term survivors. Long-term follow-up of childhood cancer survivors has documented a substantial treatment-induced increased mortality and morbidity, primaril...

Allo-hNHL (FluBuCy)
https://clinicaltrials.gov/ct2/show/NCT00785330

Jan 13th, 2020 - Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's lymphoma within this study is defined as: B-NHL: follicular lymphoma grade...

A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00944567

Aug 15th, 2017 - A non-profit study designed with the aim of analysing the phenotype and molecular characteristics (central review) and evaluating prospectively the role of PET-scans in the management of primary mediastinal lymphoma treated with conventional appro...

see more →

News  4 results

Combination Checkpoint Therapy Gains Ground in AML and MDS
https://www.onclive.com/view/combination-checkpoint-therapy-gains-ground-in-aml-and-mds

Dec 5th, 2020 - Naval Daver, MD Checkpoint-based immunee therapies have revolutionized the therapy of solid tumors by achieving breakthrough improvements in melanoma, lung cancer, renal cancer, bladder cancers, and head and neck tumors, among others. Recent stud...

Biology and Management of Diffuse Large B-cell Lymphoma
https://www.onclive.com/view/biology-and-management-of-diffuse-large-b-cell-lymphoma

Dec 5th, 2020 - Recent statistics show lymphoid malignancies to be the fifth most common cause of cancer-related death in the United States. In 2009, nearly 65,980 new cases of non-Hodgkin lymphoma (NHL) were diagnosed and 19,500 patients died despite currently a...

Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL
https://www.onclive.com/view/lead-zuma1-researcher-highlights-car-t-cell-findings-in-nhl

Nov 13th, 2020 - Frederick L. Locke, MD The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19) has shown very promising results in patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal lymphoma, and transformed fol...

COVID-19: Adjusting practice in acute leukemia care
https://www.mdedge.com/hematology-oncology/article/220042/coronavirus-updates/covid-19-adjusting-practice-acute-leukemia
Mark S. Lesney

Apr 1st, 2020 - The SARS-CoV-2 pandemic poses significant risks to leukemia patients and their providers, impacting every aspect of care from diagnosis through therapy, according to an editorial letter published online in Leukemia Research. VashiDonsk/Creative Co.

see more →